Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial
This RCT (n=800) found no difference in rate of preterm birth or stillbirth (9% each group) with the use of intramuscular 17 alpha-hydroxyprogesterone caproate compared to placebo and thus does not support use among women whose risk derives solely from HIV infection.
Source:
The Lancet HIV
SPS commentary:
Commentary is provided on the prevalence of preterm birth, the increased risk of preterm birth associated with maternal HIV, the current use of 17 alpha-hydroxyprogesterone caproate in the US and Europe and if this could be used in women with HIV.